Author:
Jones R N,Fuchs P C,Sommers H M,Gavan T L,Barry A L,Gerlach E H
Abstract
Moxalactam (LY127935) exhibited greater in vitro activity than cefamandole and tobramycin against clinical isolates of Enterobacteriaceae, Aeromonas hydrophila, and Pseudomonas maltophilia. The activities of the three drugs against other microorganisms were as follows: for staphylococci, cefamandole = tobramycin greater than moxalactam; for streptococci, cefamandole greater than moxalactam greater than tobramycin; and for Pseudomonas aeruginosa, tobramycin greater than moxalactam greater than cefamandole. Moxalactam also demonstrated significant activity against the Bacteroides fragilis group and other anaerobes. Moxalactam was comparable to cefotaxime (HR756) in its inhibition of cephalothin-resistant and aminoglycoside-resistant clinical isolates.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference21 articles.
1. Cefuroxime, an in vitro comparison with six other cephalosporins;Barry A. L.;Proc. R. Soc. Med.,1977
2. In vitro activity of LY127935;Barza M.;Antimicrob. Agents Chemother.,1979
3. HR756, the syn isomer of a new methoxyimino cephalosporin with unusual antibacterial activity;Chabbert Y. A.;Antimicrob. Agents Chemother.,1978
4. Ericsson H. M. and J. C. Sherris. 1971. Antibiotic sensitivity testing. Report of an international collaborative study. Acta Pathol. Microbiol. Scand. Sect. B Suppl. 217.
5. Susceptibility of Enterobacter to cefamandole: evidence for a high mutation rate to resistance;Findell C. M.;Antimicrob. Agents Chemother.,1976
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献